Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib (Revolution Medicines’ RASONQUE™)…
VERU INC. (VERU) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Investor and Media Contact: Samuel Fisch Executive Director, Investor Relations and Corporate Communications Email: veruinvestor@verupharma.com Veru Advances Oral Sabizabulin Following Positive Preclinical Data Showing Potent Anticancer Activity in Human Daraxonrasib
- Product
- sabizabulin
- Milestone
- trial start
- Indication
- metastatic pancreatic cancer
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The announcement positions Veru to address a high‑unmet need in KRAS‑driven pancreatic cancer, potentially expanding its market opportunity and attracting partnership interest.
Market read
First‑time disclosure of a new trial indication could trigger a short‑term rally in VERU shares and influence related oncology stocks.
What to watch
Potential competition from other KRAS inhibitors and the need for substantial funding for Phase 2.
Background
Veru Inc. (NASDAQ: VERU) is a clinical‑stage biopharma developing sabizabulin, an oral microtubule‑binding agent, and enobosarm for obesity.
Ticker impact
Veru Inc. announced new preclinical data showing sabizabulin overcomes daraxonrasib resistance and plans a Phase 2 trial for KRAS‑driven pancreatic cancer.
Potential short‑term upside of 10‑15% if market reacts to the trial advancement.
First disclosure of novel data and a clear development milestone for a late‑stage oncology asset; biotech stocks typically rally on such news.
Market effects
May lift sentiment for KRAS‑targeted oncology peers and related biotech pipelines.
US biotech sector could see modest gains.
Limited to investors focused on oncology drug development.
Counterpoint
Skeptics may argue preclinical data does not guarantee clinical success and could be overhyped.
Key entities
- CompanyVeru Inc.
Clinical‑stage biopharma developing sabizabulin.
- ExecutiveMitchell Steiner, M.D.
CEO of Veru who provided the statement.

